Check out the Endocrine Outlook podcast, brought to you by the Endocrinology Network. This episode focuses on semaglutide 1 mg as a weight loss therapy for patients who are obese or overweight.
1:52 - Key Takeaways from STEP 1 and STEP 3
4:00 - Procedures and Methods for Both Trials
9:55 - Adverse Event Profile
15:42 - Current Treatment Gaps in Obesity Management
18:25 - Is this Effect Specific to Semaglutide or all GLP1-RAs?
21:08 - If Approved, Who Should be Prescribing this Agent?
Editor's Note: This episode of the Endocrine Outlook podcast features Thomas Wadden, PhD, a professor of psychology at Perelman School of Medicine at the University of Penn. Wadden is also a principal investigator in the STEP Program, which is a series of clinical trials funded by Novo Nordisk examining subcutaneous semaglutide for inducing weight loss in patients who are obese or overweight.
During this episode, Wadden reviews the results of both STEP 1 and STEP 3, hypothesizes where this alternate dose of semaglutide could fit in treatment algorithms based on the available data, and who should ultimately be responsible for prescribing a weight loss therapy to patients. It should be mentioned his interview was recorded before the release of STEP 2 results and was therefore not included in discussion.
